TxGuard Pulmonary Valved Conduit (PVG)
Pediatric Congenital Heart Disease (e.g., right ventricular outflow tract reconstruction)
Pre-clinicalActive
Key Facts
Indication
Pediatric Congenital Heart Disease (e.g., right ventricular outflow tract reconstruction)
Phase
Pre-clinical
Status
Active
Company
About Annoviant
Annoviant is a private, pre-revenue medical device company developing the TxGuard™ regenerative tissue platform. The technology focuses on overcoming critical failures of existing biological implants—such as calcification, thrombosis, and degeneration—by creating decellularized, stabilized tissues that can be repopulated by the patient's own cells. Its initial pipeline targets pediatric and adult cardiovascular surgeries, with a pulmonary valved conduit for congenital heart disease as the lead program, supported by a $2.99M NIH grant. The company aims to reduce the need for repeat surgeries and improve long-term patient outcomes.
View full company profile